1. Home
  2. IOVA vs BLND Comparison

IOVA vs BLND Comparison

Compare IOVA & BLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • BLND
  • Stock Information
  • Founded
  • IOVA 2007
  • BLND 2012
  • Country
  • IOVA United States
  • BLND United States
  • Employees
  • IOVA N/A
  • BLND N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • BLND EDP Services
  • Sector
  • IOVA Health Care
  • BLND Technology
  • Exchange
  • IOVA Nasdaq
  • BLND Nasdaq
  • Market Cap
  • IOVA 1.0B
  • BLND 815.3M
  • IPO Year
  • IOVA N/A
  • BLND 2021
  • Fundamental
  • Price
  • IOVA $1.75
  • BLND $3.52
  • Analyst Decision
  • IOVA Strong Buy
  • BLND Buy
  • Analyst Count
  • IOVA 9
  • BLND 8
  • Target Price
  • IOVA $15.50
  • BLND $4.45
  • AVG Volume (30 Days)
  • IOVA 13.9M
  • BLND 2.4M
  • Earning Date
  • IOVA 05-08-2025
  • BLND 05-08-2025
  • Dividend Yield
  • IOVA N/A
  • BLND N/A
  • EPS Growth
  • IOVA N/A
  • BLND N/A
  • EPS
  • IOVA N/A
  • BLND N/A
  • Revenue
  • IOVA $212,679,000.00
  • BLND $164,949,000.00
  • Revenue This Year
  • IOVA $182.20
  • BLND $15.07
  • Revenue Next Year
  • IOVA $62.10
  • BLND $21.95
  • P/E Ratio
  • IOVA N/A
  • BLND N/A
  • Revenue Growth
  • IOVA 11070.12
  • BLND 15.07
  • 52 Week Low
  • IOVA $2.70
  • BLND $2.08
  • 52 Week High
  • IOVA $13.60
  • BLND $5.53
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 23.78
  • BLND 61.21
  • Support Level
  • IOVA $3.02
  • BLND $3.14
  • Resistance Level
  • IOVA $3.31
  • BLND $3.36
  • Average True Range (ATR)
  • IOVA 0.24
  • BLND 0.14
  • MACD
  • IOVA -0.09
  • BLND 0.03
  • Stochastic Oscillator
  • IOVA 4.81
  • BLND 76.42

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About BLND Blend Labs Inc.

Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.

Share on Social Networks: